



MEDICATION POLICY

Generic Name: Crizotinib

Therapeutic Class or Brand Name: Xalkori®

Applicable Drugs (if Therapeutic Class): N/A

Date of Origin: 2/1/13

Date Last Reviewed/Revised: 12/13/17

GPI Code: 2153401500

Prior Authorization Criteria (may be considered medically necessary when criteria I through IV are met):

- I. Documented diagnosis of locally advanced or metastatic (stage III or IV) non-small cell lung cancer (NSCLC).
- II. Documentation that the tumor expresses one of the following criteria A or B:
 - A. An anaplastic lymphoma kinase (ALK) translocation (the tumor is ALK-positive) as detected from an FDA-approved test.
 - B. A ROS1 rearrangement (the tumor is ROS1-positive).
- III. Minimum age requirement: 18 years old.
- IV. Prescriber is an oncologist.

Exclusion Criteria:

- N/A

Other Criteria:

- N/A

Quantity/Days Supply Restrictions:

- 60 capsules per 30 days.

Approval Length:

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

Appendix:

N/A

References:

1. <http://blue.regence.com/trgmedpol/drugs/dru265.pdf>.
2. [Medi-Span](#).
3. <http://labeling.pfizer.com/showlabeling.aspx?id=676>.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

<i>Historical Tracking Of Changes Made To Policy</i>	
<i>12/13/2017</i>	1. Policy reviewed: no changes made.
<i>10/6/2016</i>	1. Changed “II. Documentation that the tumor expresses an anaplastic lymphoma kinase (ALK) translocation (the tumor is ALK-positive) as detected from an FDA-approved test” to “II. Documentation that the tumor expresses one of the following criteria A or B: A. An anaplastic lymphoma kinase (ALK) translocation (the tumor is ALK-positive) as detected from an FDA-approved test; B. A ROS1 rearrangement (the tumor is ROS1-positive)” under Prior Authorization Criteria.
<i>4/21/2015</i>	1. Policy reviewed: no changes made.
<i>12/4/2013</i>	1. Adapted policy to new format. 2. Added GPI Code. 3. Updated references to include Medi-Span.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.